Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC. Get the latest research information from NIH.

Your Environment. Your Health.

Person Details: H. Vasken Aposhian

Superfund Research Program

H. Vasken Aposhian

University of Arizona
Department of Molecular and Cellular Biology
Biological Sciences West 262
PO Box 210106
Tucson, Arizona 85721-0106
Phone: 520-621-7565
Fax: 520-621-3709
Email: aposhian@u.arizona.edu

Projects

Research Briefs

Publications

2013

  • Naujokas MF, Anderson BE, Ahsan H, Aposhian HV, Graziano JH, Thompson CL, Suk WA. 2013. The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. Environ Health Perspect 121(3):295-302. doi:10.1289/ehp.1205875 PMID:23458756 PMCID:PMC3621177

2008

  • Chowdhury UK, Aposhian HV. 2008. Protein expression in the livers and urinary bladders of hamsters exposed to sodium arsenite. Ann N Y Acad Sci 1140:325-334. doi:10.1196/annals.1454.019 PMID:18991932

2006

  • Aposhian HV, Aposhian MM. 2006. Arsenic toxicology: five questions (review). Chem Res Toxicol 19(1):1-15. PMID:16411650
  • Chowdhury UK, Zakharyan RA, Hernandez A, Avram MD, Kopplin MJ, Aposhian HV. 2006. Glutathione-S-transferase-omega [MMA(V) reductase] knockout mice: enzyme and arsenic species concentrations in tissues after arsenate administration. Toxicol Appl Pharmacol 216(3):446-457. doi:10.1016/j.taap.2006.06.014 PMID:16930657

2005

  • Zakharyan RA, Tsaprailis G, Chowdhury UK, Hernandez A, Aposhian HV. 2005. Interactions of sodium selenite, glutathione, arsenic species, and omega class human glutathione transferase. Chem Res Toxicol 18(8):1287-1295. doi:10.1021/tx0500530 PMID:16097802

2003

  • Aposhian HV, Morgan DL, Queen HS, Maiorino RM, Aposhian MM. 2003. Vitamin C, glutathione, or lipoic acid did not decrease brain or kidney mercury in rats exposed to mercury vapor. Journal of Toxicology and Clinical Toxicology 41(4):339-347. PMID:12870874
  • Aposhian HV, Zakharyan RA, Avram MD, Kopplin MJ, Wollenberg ML. 2003. Oxidation and detoxification of trivalent arsenic species. Toxicol Appl Pharmacol 193(1):1-8. PMID:14613711
  • Aposhian HV, Zakharyan RA, Healy SM, Wildfang E, Petrick JS, Sampayo-Reyes A, Board PG, Carter DE, Mazumder G, Aposhian MM. 2003. Enzymology and Toxicity of Inorganic Arsenic. In: Arsenic Exposure and Health Effects: Proceedings of the Fifth International Conference on Arsenic Exposure and Health Effects, San Diego, California. Elsiever Science Ltd., Oxford, United Kingdom. pp.225-240.
  • Carter DE, Aposhian HV, Gandolfi A. 2003. The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: a toxicochemical review. Toxicol Appl Pharmacol 193(3):309-334. PMID:14678742
  • Loffredo CA, Aposhian HV, Cebrian ME, Yamauchi H, Silbergeld EK. 2003. Variability in human metabolism of arsenic. Environ Res 92(2):85-91. PMID:12854687
  • Marnell LL, Garcia-Vargas GG, Chowdhury UK, Zakharyan RA, Walsh B, Avram MD, Kopplin MJ, Cebrian ME, Silbergeld EK, Aposhian HV. 2003. Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol 16(12):1507-1513. PMID:14680363

2002

  • Gong Z, Jiang G, Cullen WR, Aposhian HV. 2002. Determination of arsenic metabolic complex excreted in human urine after administration of sodium 2,3-dimercapto-1-propane sulfonate. Chem Res Toxicol 15(10):1318-1323. PMID:12387631
  • Liu J, Zheng B, Aposhian HV, Zhou Y, Chen M, Waalkes MP. 2002. Chronic arsenic poisoning from burning high-arsenic-containing coal in Guizhou, China. Environ Health Perspect 110(2):119-122. PMID:11836136
  • Radabaugh TR, Sampayo-Reyes A, Zakharyan RA, Aposhian HV. 2002. Arsenate reductase II. Purine nucleoside phophorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem Res Toxicol 15(5):692-698.

2001

  • Aposhian HV, Aposhian MM. 2001. Arsenic mobilization by DMPS. In: Arsenic Exposure and Health Effects IV. Elsevier, New York, NY. pp.397-406.
  • Aposhian HV, Gurzau ES, Le X, Gurzau A, Zakharyan RA, Cullen WR, Healy SM, Gonzalez-Ramirez D, Morgan DL, Sampayo-Reyes A, Wildfang E, Radabaugh TR, Petrick JS, Mash EA, Aavula RB, Aposhian MM. 2001. The discovery, importance and siginificance of monomethyl-arsonous acid (MMAIII) in urine of humans exposed to inorganic arsenic. In: Arsenic Exposure and Health Effects IV. Elsevier, New York, NY. pp.305-314.
  • Petrick JS, Jagadish B, Mash EA, Aposhian HV. 2001. Monomethylarsonous acid (MMAIII) and arsenite: LD50 in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol 14(6):651-656. PMID:11409934
  • Wildfang E, Radabaugh TR, Aposhian HV. 2001. Enzymatic methylation of arsenic compounds. IX. Liver arsenite methyltransferase and arsenate reductase activities in primates. Toxicology 168(3):213-221. PMID:11684318
  • Zakharyan RA, Sampayo-Reyes A, Healy SM, Tsaprailis G, Board PG, Liebler DC, Aposhian HV. 2001. Human monomethylarsonic acid (MMAV) reductase is a member of the glutathione-S-transferase superfamily. Chem Res Toxicol 14(8):1051-1057. PMID:11511179

2000

  • Aposhian HV, Aposhian MM. 2000. Arsenic mobilization by DMPS. In: Proceedings of the Fourth International Conference on Arsenic Exposure and Health Effects. San Diego, CA.
  • Aposhian HV, Gurzau ES, Le X, Gurzau A, Healy SM, Lu X, Ma M, Yip L, Zakharyan RA, Maiorino RM, Dart RC, Tircus MG, Gonzalez-Ramirez D, Morgan DL, Avram D, Aposhian MM. 2000. Occurrence of monomethylarsonous acid (MMAIII) in urine of humans exposed to inorganic arsenic. Chem Res Toxicol 13(8):693-697. PMID:10956055
  • Aposhian HV, Gurzau ES, Le X, Gurzau A, Zakharyan RA, Cullen WR, Healy SM, Gonzalez-Ramirez D, Morgan DL, Sampayo-Reyes A, Wildfang E, Radabaugh TR, Petrick JS, Mash EA, Aavula RB, Aposhian MM. 2000. The discovery, importance and significance of monomethyl- arsonous acid (MMAIII) in urine of humans exposed to inorganic arsenic. In: Proceedings of the Fourth International Conference on Arsenic Exposure and Health Effects. San Diego, CA.
  • Aposhian HV, Zheng B, Aposhian MM, Le X, Cebrian ME, Cullen WR, Zakharyan RA, Ma M, Dart RC, Cheng Z, Andrewes P, Yip L, O'Malley GF, Maiorino RM, Van Voorhies W, Healy SM, Titcomb A. 2000. DMPS-arsenic challenge test: II. Modulation of arsenic species, including monomethylarsonous acid (MMAIII ), excreted in human urine. Toxicol Appl Pharmacol 165(1):74-83. PMID:10814555
  • Gailer J, George GN, Pickering IJ, Prince RC, Ringwald SC, Pemberton JE, Glass RS, Younis HS, DeYoung DW, Aposhian HV. 2000. A metabolic link between arsenite and selenite: The seleno-bis(S-glutathionyl) arsinium ion. J Am Chem Soc 122(19):4637-4639.
  • Le X, Lu X, Ma M, Cullen WR, Aposhian HV, Zheng B. 2000. Speciation of key arsenic metabolic intermediates in human urine. Anal Chem 72(21):5172-5177. PMID:11080860
  • Le X, Ma M, Lu X, Cullen WR, Aposhian HV, Zheng B. 2000. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ Health Perspect 108(11):1015-1018. PMID:11102289
  • Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Aposhian HV. 2000. Monomethylarsonous acid (MMAIII) is more toxic than arsenite in chang human hepatocytes. Toxicol Appl Pharmacol 163(2):203-207. PMID:10698679
  • Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Aposhian HV. 2000. The most toxic arsenical in the inorganic arsenic biotransformation pathway. In: Proceedings of the Fourth International Conference on Arsenic Exposure and Health Effects. San Diego, CA.
  • Radabaugh TR, Aposhian HV. 2000. Enzymatic reduction of arsenic compounds in mammalian systems: reduction of arsenate to arsenite by human liver arsenate reductase. Chem Res Toxicol 13(1):26-30. PMID:10649963
  • Sampayo-Reyes A, Zakharyan RA, Aposhian HV. 2000. Monomethylarsonic acid MMA (V) reductase activity in hamster tissues. In: Proceedings of the Fourth International Conference on Arsenic Exposure and Health Effects. San Diego, CA.
  • Sampayo-Reyes A, Zakharyan RA, Healy SM, Aposhian HV. 2000. Monomethylarsonic acid (MMAV) reductase and monomethylarsonous acid (MMAIII) in hamster tissue. Chem Res Toxicol 13(11):1181-1186.
  • Wildfang E, Healy SM, Aposhian HV. 2000. Arsenic. In: Molecular Biology and Toxicology of Metals. Taylor and Francis Inc., London, United Kingdom. pp.75-112.

1999

  • Aposhian HV, Zakharyan RA, Wildfang E, Healy SM, Radabaugh TR, Bogdan GM, Powell LA, Aposhian MM. 1999. How is inorganic arsenic detoxified?. In: Proceedings of the San Diego Arsenic Symposium. San Diego, CA.
  • Healy SM, Wildfang E, Zakharyan RA, Aposhian HV. 1999. Diversity of inorganic arsenite biotransformation. Biol Trace Elem Res 68(3):249-266. PMID:10328340
  • Zakharyan RA, Aposhian HV. 1999. Arsenite methylation by methylvitamin B12 and glutathione does not require an enzyme. Toxicol Appl Pharmacol 154(30):287-291. PMID:9931288
  • Zakharyan RA, Aposhian HV. 1999. Enzymatic reduction of arsenic compounds in mammalian systems: the rate limiting enzyme of rabbit liver arsenic biotransformation is MMAV reductase. Chem Res Toxicol 12(12):1278-1283. PMID:10604879
  • Zakharyan RA, Ayala-Fierro F, Cullen WR, Carter DE, Aposhian HV. 1999. Enzymatic methylation of arsenic compounds: VII. Monomethylarsonous acid (MMAIII) is the substrate for MMA methyltransferase of rabbit liver and human hepatocytes. Toxicol Appl Pharmacol 158(1):9-15. PMID:10387927

1998

  • Aposhian HV. 1998. Mobilization of mercury and arsenic in humans by sodium 2,3-dimercapto-1-propane sulfonate (DMPS). Environ Health Perspect 106(Suppl.4):1017-1025. PMID:9703487
  • Aposhian HV, Zakharyan RA, Healy SM, Wildfang E, Radabaugh TR, Badghisi H, Aposhian MM. 1998. Biodiversity of inorganic arsenite methyltransferases. Environ Health Perspect 42(1-S):353.
  • Bittner AC, Echeverria D, Woods JS, Aposhian HV, Naleway CA, Martin MD, Mahurin RK, Heyer NJ, Cianciola ME. 1998. Behavioral effects of low level exposure to Hgo among dental professionals: A cross- study evaluation of psychomotor effects. Neurotoxicol Teratol 20(4):429-439. PMID:9697969
  • Echeverria D, Aposhian HV, Woods JS, Heyer NJ, Aposhian MM, Bittner AC, Mahurin RK, Cianciola ME. 1998. Neurobehavioral effects from exposure to dental amalgam Hgo: new distinctions between recent exposure and Hg body burden. FASEB J 12(11):971-980. PMID:9707169
  • Healy SM, Casarez EA, Ayala-Fierro F, Aposhian HV. 1998. Enzymatic methylation of arsenic compounds: V. Arsenite methyltransferase activity in tissues of mice. Toxicol Appl Pharmacol 148(1):65-70. PMID:9465265
  • Wildfang E, Zakharyan RA, Aposhian HV. 1998. Enzymatic methylation of arsenic compounds: VI. Characterization of hamster liver arsenite and monomethylarsonic acid methyltransferase activities in vitro. Toxicol Appl Pharmacol 152(2):366-375. PMID:9853005
  • Wildfang E, Zakharyan RA, Aposhian HV. 1998. Hamster and rabbit arsenite and MMA methyltransferase kinetics. In: Proceedings of the Symposium on Risk Considerations for Environmental Health and Safety. The University of Arizona, Tucson, AZ.
  • Wildfang E, Zakharyan RA, Aposhian HV. 1998. Hamster and rabbit arsenite and MMA methyltransferase kinetics: comparisons of in vitro properties. Environ Health Perspect 42(1-S):283.
  • Zakharyan RA, Healy SM, Chaga G, Aposhian HV. 1998. Purification and properties of the arsenite methylating isoenzymes of rabbit liver. Environ Health Perspect 42:332.

1997

  • Aposhian HV. 1997. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol 37:397-419. PMID:9131259
  • Aposhian HV, Arroyo AP, Cebrian ME, Del Razo LM, Hurlbut KM, Dart RC, Gonzalez-Ramirez D, Kreppel H, Smith AH, Gonsebatt ME, Ostrosky-Wegman P, Aposhian MM. 1997. Increased urinary excretion of monomethylarsonic acid in humans given DMPS. Environ Health Perspect 36(1,2):5.
  • Aposhian HV, Arroyo AP, Cebrian ME, Del Razo LM, Hurlbut KM, Dart RC, Gonzalez-Ramirez D, Kreppel H, Speisky H, Smith AH, Gonsebatt ME, Ostrosky-Wegman P, Aposhian MM. 1997. DMPS-Arsenic challenge test: I-increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sufolnate. J Pharmacol Exp Ther 282(1):192-200. PMID:9223554
  • Aposhian HV, Zakharyan RA, Healy SM, Wildfang E, Radabaugh TR, Clayton DB, Badghisi H, Aposhian MM. 1997. Species and structural diversity of arsenite methyltransferases. In: Proceedings of Arsenic: Health Effects, Mechanisms of Actions, and Research Issues. Hunt Valley, MD.
  • Aposhian HV, Zakharyan RA, Wu Y, Healy SM, Aposhian MM. 1997. Enzymatic methylation of arsenic compounds: II. An overview. In: Arsenic Exposure and Human Health, Vol. 2. Chapman & Hall, London, United Kingdom.
  • Cianciola ME, Echeverria D, Martin MD, Aposhian HV, Woods JS. 1997. Epidemiologic assessment of measures used to indicate low level exposure to mercury vapor (Hg). J Toxicol Environ Health A 52(1):19-33. doi:10.1080/00984109708984050 PMID:9269320
  • Cianciola ME, Echeverria D, Martin MD, Aposhian HV, Woods JS. 1997. Epidemiologic assessment of measures used to indicate low level exposure to mercury vapor (Hg0). Environ Health Perspect 36(1,2):6.
  • Healy SM, Casarez EA, Aposhian HV. 1997. Arsenite methyltransferase activity in various tissues of B6C3F1 mice administered subchronic doses of sodium arsenate. Environ Health Perspect 36(1,2):313.
  • Healy SM, Radabaugh TR, Badghisi H, Wildfang E, Zakharyan RA, Aposhian MM, Aposhian HV. 1997. A challenge to the putative route of arsenic detoxification. In: Proceedings of Arsenic: Health Effects, Mechanisms of Actions, and Research Issues. Hunt Valley, MD.
  • Healy SM, Zakharyan RA, Aposhian HV. 1997. Enzymatic methylation of arsenic compounds: IV. In vitro and in vivo deficiency of the methylation of arsenite and monomethylarsonic acid in the guinea pig. Mutat Res Rev Mutat Res 386(3):229-239. PMID:9219561
  • Keith RL, Setiarahardjo I, Fernando Q, Aposhian HV, Gandolfi A. 1997. Utilization of renal slices to evaluate the efficacy of chelators to remove mercury from the kidney. Toxicology 116:67-75. PMID:9020508
  • Radabaugh TR, Aposhian HV. 1997. Enzymatic reduction of arsenate to arsenite in mammalian liver. Environ Health Perspect 36(1,2):293.
  • Wildfang E, Zakharyan RA, Aposhian HV. 1997. Hamster and rabbit arsenite and MMA methyltransferase kinetics: Comparisons of in vitro properties. In: Proceedings of Arsenic: Health Effects, Mechanisms of Actions, and Research Issues. Hunt Valley, MD.
  • Wildfang E, Zakharyan RA, Aposhian HV. 1997. Lack of in vitro arsenite and monomethylarsonic acid methyltransferase activity in the chimpanzee and squirrel monkey. Environ Health Perspect 36(1,2):293.
  • Zakharyan RA, Healy SM, Chaga G, Aposhian HV. 1997. Purification and properties of the arsenite methylating isoenzymes of rabbit liver. In: Proceedings of Arsenic: Health Effects, Mechanisms of Actions, and Research Issues. Hunt Valley, MD.

1996

  • Aposhian HV. 1996. Arsenic toxicology: Does methylation of arsenic species have an evolutionary significance?. In: Metals Ions in Biology and Medicine: Proceedings of the Fourth International Symposium on Metal Ions in Biology and Medicine. John Libbey Eurotext, Montrouge, France. pp.399-401.
  • Aposhian HV, Zakharyan RA, Wu Y, Healy SM, Wildfang E, Radabaugh TR, Badghisi H, Aposhian MM. 1996. Does methylation of arsenite have evolutionary significance? The diversity of the reductase and methyltransferases of arsenic metabolism. In: Proceedings of Modulation of Chemical Toxicity and Risk Assessment. The University of Arizona, Tucson, AZ.
  • Aposhian MM, Maiorino RM, Xu Z, Aposhian HV. 1996. Sodium 2,3-dimercapto-1-propanesulfonate (DMPS) treatment does not redistribute lead or mercury to the brain of rats. Toxicology 109(1):49-55. PMID:8619252
  • Healy SM, Zakharyan RA, Aposhian HV. 1996. Does the guinea pig methylate arsenite and MMA?. Environ Health Perspect 30(1,2):89.
  • Maiorino RM, Gonzalez-Ramirez D, Zuniga-Charles M, Xu Z, Hurlbut KM, Aposhian MM, Dart RC, Woods JS, Ostrosky-Wegman P, Gonsebatt ME, Aposhian HV. 1996. Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. III. Urinary mercury after exposure to mercurous chloride. J Pharmacol Exp Ther 277(2):938-944. PMID:8627576
  • Maiorino RM, Xu Z, Aposhian HV. 1996. Determination and metabolism of dithiol chelating agents XVII In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides. J Pharmacol Exp Ther 277(1):375-384. PMID:8613944
  • Zakharyan RA, Wildfang E, Aposhian HV. 1996. Enzymatic methylation of arsenic compounds: III. The marmoset and tamarin, but not the rhesus, monkeys are deficient in methyltransferases that methylate inorganic arsenic. Toxicol Appl Pharmacol 140(1):77-84. PMID:8806872

1995

  • Aposhian HV, Gonzalez-Ramirez D, Maiorino RM, Zuniga-Charles M, Hurlbut KM, Aposhian MM, Dart RC. 1995. DMPS (DIMAVAL) as a challenge test to assess the mercury and arsenic body/kidney load in humans and as a treatment of mercury toxicity. In: Proceedings of the Pacific Basin Conference on Hazardous Waste, Edmonton, Alberta, Canada, 7-12 May, 1995. Edmonton, Alberta, Canada.
  • Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, Zuniga-Charles M, Xu Z, Hurlbut KM, Junco-Munoz P, Dart RC, Aposhian MM. 1995. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology 97(1-3):23-38. PMID:7716789
  • Aposhian HV, Zakharyan RA, Wu Y, Bogdan GM, Healy SM. 1995. Purification and properties of the arsenite methylating enzymes of rabbit liver. International Congenital Toxicology 7:86-88.
  • Aposhian HV, Zakharyan RA, Wu Y, Bogdan GM, Healy SM. 1995. Purification and properties of the arsenite methylating enzymes of rabbit liver. In: Proceedings of the Vth COMTOX Symposium on Toxicology and Clinical Chemistry of Metals. pp.25.
  • Hasal SJ, Aposhian HV, Gandolfi A, Brendel K. 1995. Human and rabbit renal cortical slices in aerated submersion culture as a model to evaluate heavy metal chelators. Environ Health Perspect 15:310.
  • Zakharyan RA, Wu Y, Aposhian HV. 1995. Enzymatic assay and purification of arsenic methyltransferase from rabbit liver. Environ Health Perspect 15:308.
  • Zakharyan RA, Wu Y, Bogdan GM, Aposhian HV. 1995. Enzymatic methylation of arsenic compounds: I. Assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Chem Res Toxicol 8(8):1029-1038. PMID:8605285
Back
to Top